Lensar reports Q1 EPS (19c), consensus (28c)

Reports Q1 revenue $10.588M, consensus $10.550M .”Recognition of ALLY’s advantages, its ability to achieve higher efficiencies for surgeons and staff as well as better surgical outcomes for patients, allowed us to deliver continued 20%+ revenue growth in the first quarter of 2024. Total revenue for the quarter was $10.6 million, up 28% over the first quarter of 2023. Moreover, procedure volume grew by 23% in the U.S., our largest market and the only country where ALLY is currently marketed,” said Nick Curtis, President and CEO of LENSAR. “More importantly, our U.S. procedure share continued to grow, increasing 1.5% in the first quarter from the fourth quarter of 2023, as reported by Market Scope. This growth represented LENSAR’s highest single-quarter procedure share gain since we launched ALLY. We have achieved 4.3% growth in U.S. procedure share since ALLY’s launch, and I believe that we are well positioned to continue to grow both in the U.S. and internationally upon receipt of the regulatory approvals anticipated later this year.” First Quarter 2024 Financial Results